The call reflected a balanced view of Hologic's performance, with strong non-product revenue growth and diagnostics performance offset by challenges such as revenue declines, geopolitical issues in China, and the impact of tariffs.

Company Guidance -

Q2 2025

During Hologic's second quarter fiscal 2025 earnings call, several key financial metrics and guidance updates were provided. The company reported total revenue of $1.005 billion, a decrease of 0.5% in constant currency, yet toward the upper end of their guidance range. Non-GAAP earnings per share were $1.03, aligning with the high end of their guidance and remaining flat year-over-year. The Diagnostics segment saw revenue of $453.6 million, with a 5.2% growth excluding COVID-related sales. Breast Health revenue was $356.2 million, while Surgical revenue increased to $162.5 million. The company highlighted challenges in China, leading to a reduction in sales expectations, and also noted a $20 million to $25 million quarterly impact from tariffs. Despite these headwinds, Hologic maintained its full-year revenue guidance of $4.05 billion to $4.10 billion, adjusting non-GAAP EPS guidance to $4.15 to $4.25. The call emphasized strong growth in non-product revenue, which represented 21% of total revenue, and highlighted strategic initiatives to drive future growth amid macroeconomic challenges.

Strong Non-Product Revenue Growth

Non-product revenue grew by 12%, driven by strong growth in breast health service, which accounted for $212.6 million of overall revenue and represented 21% of total revenue.

Diagnostics Business Performance

Diagnostics revenue grew by 5.2% excluding COVID-related sales, led by molecular diagnostics growth of 7.8%, driven by the BV/CV/TV assay and respiratory assays.

Operating Cash Flow and Financial Flexibility

Generated $169.5 million in operating cash flow and maintained a strong balance sheet with $1.43 billion in cash and equivalents, and an adjusted net leverage ratio of 0.8 times.

Employee Engagement

High employee engagement with scores in the 98th percentile compared to similar companies, and 99% of employees agree that Hologic's mission makes their jobs important.

Hologic (HOLX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HOLX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 23, 2025	2025 (Q3)	1.05 / -	1.06	―	―	―
May 01, 2025	2025 (Q2)	1.02 / 1.03	1.03	0.00% (0.00)
Feb 05, 2025	2025 (Q1)	1.01 / 1.03	0.98	5.10% (+0.05)	―
Nov 04, 2024	2024 (Q4)	1.01 / 1.01	0.89	13.48% (+0.12)
Jul 29, 2024	2024 (Q3)	1.02 / 1.06	0.93	13.98% (+0.13)
May 02, 2024	2024 (Q2)	0.98 / 1.03	1.06	-2.83% (-0.03)
Feb 01, 2024	2024 (Q1)	0.95 / 0.98	1.07	-8.41% (-0.09)
Nov 09, 2023	2023 (Q4)	0.84 / 0.89	0.82	8.54% (+0.07)
Jul 31, 2023	2023 (Q3)	0.89 / 0.93	0.95	-2.11% (-0.02)
May 01, 2023	2023 (Q2)	0.88 / 1.06	2.07	-48.79% (-1.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HOLX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 01, 2025	$57.28	$54.16	-5.45%
Feb 05, 2025	$72.80	$65.45	-10.10%
Nov 04, 2024	$83.72	$78.80	-5.88%
Jul 29, 2024	$79.64	$82.51	+3.60%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.